Spark Therapeutics to Participate in AAO Annual Meeting
October 10 2016 - 7:30AM
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy
company seeking to transform the lives of patients with
debilitating genetic diseases by developing potential one-time,
life-altering treatments, announced today that members of company
management and a principal investigator will participate in the
following American Association of Ophthalmology (AAO) Annual
Meeting events between Oct. 13 and Oct. 18:
2016 Ophthalmology Innovation Summit, or OIS@AAO, at the Hyatt
Regency Chicago
- Jeffrey D. Marrazzo, chief executive officer, will participate
in the Gene Therapy Breakfast Break-Out Panel discussion on
Thursday, Oct. 13, at 7:30 a.m. (CDT)
Retina Days Subspecialty Meeting, at the McCormick Center in
Chicago
- Albert M. Maguire, M.D., professor of ophthalmology at the
Perelman School of Medicine of the University of Pennsylvania, will
talk about “Gene Therapy for Leber Amaurosis Type 2 – Clinical
Trials Results,” including data from the pivotal Phase 3 trial of
voretigene neparvovec on Friday, Oct. 14, at 12:13 p.m. (CDT)
Additionally, the company will have a booth presence in the
McCormick Center exhibit hall throughout the AAO meeting. Visit us
at Booth 1980.
About Spark TherapeuticsSpark Therapeutics, a
fully integrated gene therapy company, is seeking to transform the
lives of patients with debilitating genetic diseases by developing
potential one-time, life-altering treatments. Spark Therapeutics’
validated gene therapy platform is being applied to a range of
clinical and preclinical programs addressing serious genetic
diseases, including inherited retinal diseases, liver-associated
diseases, such as hemophilia, and neurodegenerative diseases. Spark
Therapeutics’ validated platform has successfully delivered
proof-of-concept data with investigational gene therapies in the
eye and liver. Spark Therapeutics’ most advanced product
candidate, voretigene neparvovec (formerly referred to as
SPK-RPE65), which has received both breakthrough therapy and orphan
product designations, has reported top-line results from a pivotal
Phase 3 clinical trial for the potential treatment of a rare
blinding condition. Spark Therapeutics’ hemophilia franchise has
two lead assets: SPK-9001 in a Phase 1/2 trial for
hemophilia B and SPK-8011, a preclinical candidate for hemophilia
A. To learn more, please visit www.sparktx.com.
Spark Therapeutics Corporate Contacts
Stephen W. Webster, Chief Financial Officer
Daniel Faga, Chief Business Officer
(855) SPARKTX (1-855-772-7589)
Media Contact
Dan Quinn
Ten Bridge Communications
(781) 475-7974
dan@tenbridgecommunications.com
Onconetix (NASDAQ:ONCE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Onconetix (NASDAQ:ONCE)
Historical Stock Chart
From Sep 2023 to Sep 2024